A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
Why a hotel room in New York costs $500 a night
In a recent op-ed in The Wall Street Journal titled “Why a Hotel Room in NY Costs $500,” Michael Salinger (CRA consultant and Boston University professor) and...